US equities |
SPCX $167.66 ▲+5.47% NVDA $236.12 ▲+0.93% MU $1,065.50 ▼-0.87% TSLA $378.09 ▲+2.02% MSFT $526.11 ▲+1.66% SNDK $1,710.57 ▼-0.55% INTC $117.31 ▼-1.70% META $744.00 ▲+2.19%
FinancialContent

Articles published by Indivior Pharmaceuticals Inc.

News headline image
Indivior Pharmaceuticals, Inc. Declares Special Cash Dividend
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
Tickers INDV
News headline image
Indivior Reports Second Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
Tickers INDV
News headline image
Indivior to Report Second Quarter 2026 Financial Results and Host Webcast
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
Tickers INDV
News headline image
New Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
Tickers INDV
News headline image
Indivior to Participate in Upcoming Investor Conferences
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
Tickers INDV
News headline image
Indivior Announces $175 Million Accelerated Share Repurchase
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
Tickers INDV
News headline image
Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
Tickers INDV
News headline image
Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
Tickers INDV
News headline image
Survey of Correctional Facility Staff: Monthly Opioid Treatment Shot May Help Reduce Medication Misuse
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
Tickers INDV
News headline image
Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
Tickers INDV
News headline image
New Cost Impact Model Highlights Potential for Monthly Injectable Buprenorphine to Reduce Staffing Burdens in Correctional Facilities
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
Tickers INDV
News headline image
National Survey Finds Only 58% of U.S. Correctional Facilities Offer Medications for Opioid Use Disorder
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
Tickers INDV
News headline image
Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
Tickers INDV
News headline image
Indivior Announces Proposed Convertible Senior Notes Offering
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
Tickers INDV
News headline image
New Study Shows Adherence to Monthly Injectable Buprenorphine Linked to Lower Healthcare Utilization and Costs in Opioid Use Disorder
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
Tickers INDV
News headline image
Indivior Reports Fourth Quarter and Full-Year 2025 Financial Results
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
Tickers INDV
News headline image
Indivior to Participate in Upcoming Investor Conferences
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
Tickers INDV
News headline image
Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26ᵗʰ
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
Tickers INDV
News headline image
Indivior Announces Completion of Redomiciliation to the United States
From Indivior Pharmaceuticals Inc.
Via GlobeNewswire
Tickers INDV